ASTRAZENECA ANNUAL REVIEW 2006 SHAREHOLDER INFORMATION ASTRAZENECA 2002 2003 2004 2005 2006 Ordinary Shares in issue millions At year end 1,719 1,693 1,645 1,581 1,532 Weighted average for year 1,733 1,709 1,673 1,617 1,564 Stock market price per $0.25 Ordinary Share Highest pence 3625 2868 2749 2837 3529 Lowest pence 1799 1820 1863 1861 2574 At year end pence 2220 2680 1889 2829 2744 Percentage analysis at 31 December 2006 of issued share capital By size of account 2006 No.
At 31 December 2006, there were approximately 100,000 holders of American Depositary Receipts ADRs representing 10.48% of the issued share capital and 157,000 holders of shares held under the VPC Services Agreement representing 23.32% of the issued share capital.
The ADRs, each of which is equivalent to one Ordinary Share, are issued by JPMorgan Chase Bank.
2006 DIVIDEND $ Pence SEK Payment date First interim dividend 0.49 26.6 3.60 18 September 2006 Second interim dividend 1.23 63.0 8.60 19 March 2007 Total 1.72 89.6 12.20 DIVIDEND PAYMENTS The record date for the second interim dividend for 2006, payable on 19 March 2007 in the UK, the US and Sweden, is 9 February 2007.
Shares trade ex-dividend on the London and Stockholm Stock Exchanges from 7 February 2007 and ADRs trade ex-dividend on the New York Stock Exchange from the same date.
Dividends will normally be paid as follows: First interim: Announced in July and paid in September.
Second interim: Announced in January February and paid in March.
The record date for the first interim dividend for 2007, payable on 17 September 2007 in the UK, the US and Sweden, is 10 August 2007.
FINANCIAL CALENDAR 2007 26 April 2007 Annual General Meeting and announcement of first quarter 2007 results 26 July 2007 Announcement of second quarter and half year 2007 results 1 November 2007 Announcement of third quarter and nine months 2007 results 48 STATEMENTS OF COMPETITIVE CAUTIONARY STATEMENT HOW TO OBTAIN THE FULL POSITION REGARDING FORWARD-LOOKING ANNUAL REPORT AND FORM STATEMENTS 20-F INFORMATION Except as otherwise stated, market information in this Annual Review regarding The purpose of this Annual Review is to The Company publishes an Annual Report the position of our business or products provide information to the members of the and Form 20-F Information and, for investors relative to its or their competition is based Company.
In order, inter alia, to utilise the safe not needing the full detail of that document, upon published statistical data for the harbour provisions of the US Private this Annual Review.
Both documents are 12 months ended 30 September 2006, Securities Litigation Reform Act 1995, we are available on our website, astrazeneca.
obtained from IMS Health, a leading supplier providing the following cautionary statement: The Annual Review is sent to all shareholders of statistical data to the pharmaceutical This Annual Review contains certain forwardon the date of publication, unless they have industry.
Except as otherwise stated, these looking statements with respect to the elected to receive the full Annual Report and market share and industry data from IMS operations, performance and financial Form 20-F Information by writing to the Health have been derived by comparing condition of the AstraZeneca Group.
Alternatively, our sales revenue to competitors and total we believe our expectations are based on shareholders may elect to receive noti cation market sales revenues for that period.
For the reasonable assumptions, any forward-looking by e-mail of the publication of financial reports purposes of this Annual Review, references to statements, by their very nature, involve risks by registering with Shareview.
Printed copies the world pharmaceuticals market or similar and uncertainties and may be in uenced by can be obtained by writing to the Company phrases are to 52 countries contained in IMS factors that could cause actual outcomes and Secretary.
Healths MIDAS Quantum database, which results to be materially different from those amount to approximately 95% in value of the predicted.
The forward-looking statements countries audited by IMS Health.
re ect knowledge and information available at SHAREVIEW the date of the preparation of this Annual Review and the Company undertakes no AstraZenecas shareholders with internet SHAREGIFT obligation to update these forward-looking access may visit shareview.
co. uk and register statements.
We identify the forward-looking their details to create a portfolio.
Shareview AstraZeneca welcomes and values all of its statements by using the words anticipates, is a free and secure on-line service from the shareholders, no matter how many or how believes, expects, intends and similar Companys registrars, Lloyds TSB Registrars, few shares they own.
However, shareholders expressions in such statements.
Important which gives access to shareholdings including who have only a small number of shares factors that could cause actual results to differ balance movements, indicative share prices whose value makes it uneconomic to sell materially from those contained in forwardand information about recent dividends.
them, either now or at some stage in the looking statements, certain of which are future, may wish to consider donating them beyond our control, include, among other to charity through ShareGift, an independent things: the loss or expiration of patents, TRADE MARKS charity share donation scheme.
One feature marketing exclusivity or trade marks: the risk of the scheme is that there is no gain or loss of substantial adverse litigation government Trade marks of the AstraZeneca group of for UK capital gains tax purposes on gifts of investigation claims and insuf cient insurance companies appear throughout this document shares through ShareGift and it may now also coverage: exchange rate uctuations: the risk in italics.
AstraZeneca, the AstraZeneca be possible to obtain UK income tax relief on that R&D will not yield new products that logotype and the AstraZeneca symbol are the donation.
Further information about achieve commercial success: the risk that all trade marks of the AstraZeneca group ShareGift can be found on its website, strategic alliances will be unsuccessful: the of companies.
Trade marks of companies other sharegift.
org, or by contacting ShareGift on impact of competition, price controls and than AstraZeneca appear with a or sign.
020 7337 0501 or at 46 Grosvenor Street, price reductions: taxation risks: the risk of London W1K 3HN.
More information about substantial product liability claims: the impact the UK tax position on gifts of shares to of any failure by third parties to supply USE OF TERMS ShareGift can be obtained from HM Revenue materials or services: the risk of failure to & Customs, whose website address is manage a crisis: the risk of delay to new In this Annual Review, unless the context hmrc.
The share transfer form needed product launches: the dif culties of obtaining otherwise requires, AstraZeneca, the Group, to make a donation may be obtained from and maintaining regulatory approvals for the Company, we, us and our refer to the Companys registrars, Lloyds TSB products: the risk of failure to observe ongoing AstraZeneca PLC and its consolidated Registrars, whose address can be found on regulatory oversight: the risk that new entities.
the back cover of this document.
ShareGift products do not perform as we expect: the is administered by The Orr Mackintosh risk of environmental liabilities: the risks Foundation, registered charity number associated with conducting business in 1052686. emerging markets: the risk of reputational damage: and the risk of product counterfeiting.
Nothing in this Annual Review should be construed as a pro t forecast.
CONTACT INFORMATION REGISTERED OFFICE AND CORPORATE HEADQUARTERS ADDRESS AstraZeneca PLC 15 Stanhope Gate London W1K 1LN UK Tel: 44 0 20 7304 5000 Fax: 44 0 20 7304 5151 INVESTOR RELATIONS CONTACTS UK: as above or e-mail IR@astrazeneca.
com Sweden: AstraZeneca AB SE-151 85 Sdertlje Sweden Tel: 46 0 8 553 260 00 Fax: 46 0 8 553 290 00 or e-mail IR@astrazeneca.
com US: Investor Relations AstraZeneca Pharmaceuticals LP 1800 Concord Pike PO Box 15438 Wilmington fide 19850-5438 US Tel: 1 302 886 3000 Fax: 1 302 886 2972 REGISTRAR AND TRANSFER OFFICE Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA UK Tel freephone in the UK : 0800 389 1580 Tel outside the UK : 44 121 415 7033 SWEDISH SECURITIES REGISTRATION CENTRE VPC AB PO Box 7822 SE-103 97 Stockholm Sweden Tel: 46 0 8 402 9000 US DEPOSITARY JPMorgan Chase Bank JPMorgan Service Center PO Box 3408 South Hackensack NJ 07606-3408 US The paper used in this review is made using pulp from sawmill residues, forest thinnings and wood from PEFC Tel toll free in the US : 888 697 8018 certi ed sustainable forests.
All mill broke is recycled and Tel outside the US : 1 201 680 6630 accounts for up to 25% of the total bre content.
Pulps are Elemental Chlorine Free ECF and the manufacturing mill holds ISO 14001 and EMAS environmental management accreditations.
Designed by Addison Corporate Marketing Ltd. AstraZeneca PLC 1 February 2007 ASTRAZENECA.
